MARKET

SVRA

SVRA

Savara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.190
+0.060
+5.31%
After Hours: 1.190 0 0.00% 16:00 09/25 EDT
OPEN
1.120
PREV CLOSE
1.130
HIGH
1.210
LOW
1.120
VOLUME
141.14K
TURNOVER
--
52 WEEK HIGH
5.48
52 WEEK LOW
0.6900
MARKET CAP
64.41M
P/E (TTM)
-0.8214
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Checkpoint Therapeutics, Nano-X Imaging leads healthcare gainers, Evofem Biosciences, Satsuma Pharmaceuticals among major losers
Gainers: Checkpoint Therapeutics (CKPT) +29%, Nano-X Imaging (NNOX) +21%, Biofrontera AG (BFRA) +20%, Zymeworks (ZYME) +14%, MEI Pharma (MEIP) +12%.Losers: Evofem Biosciences (EVFM) -20%, Satsuma Pharmaceuticals (STSA) -11%, Corbus Pharmaceuticals Holdings (CRBP) -10%, Savara (SVRA) -9%, BiondVax Pharmaceuticals (BVXV) -8%.
Seekingalpha · 09/11 15:05
Savara plummets 11% premarket; appoints interim CEO
Savara (SVRA) down 11% premarket. CEO Rob Neville is moving on from his role and as a board member; Matthew Paul, has been appointed as Chairman and the interim.Taneli Jouhikainen, President and Chief Business Officer,
Seekingalpha · 09/11 13:29
Savara Announces Senior Management Changes
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities. The Company’s Board of Directors has appointed Matthew Pauls
Business Wire · 09/11 13:05
Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT.
Business Wire · 09/09 20:05
Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled "Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis," appears in the September 7, 2020 online version
Business Wire · 09/08 13:05
Akebia Anemia Data, And Other News: The Good, Bad And Ugly Of Biopharma
Akebia reports data for its anemia drug candidate.Abbott moves ahead with Drug-Eluting resorbable scaffold.Savara announces discontinuing Molgradex for NTM lung infection.
Seekingalpha · 09/07 03:16
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)
Business Wire · 09/03 20:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SVRA. Analyze the recent business situations of Savara through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SVRA stock price target is 4.825 with a high estimate of 7.00 and a low estimate of 1.300.
EPS
Institutional Holdings
Institutions: 123
Institutional Holdings: 31.90M
% Owned: 58.93%
Shares Outstanding: 54.13M
TypeInstitutionsShares
Increased
33
2.75M
New
28
-1.49M
Decreased
12
553.22K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Chief Executive Officer/Director
Matthew Pauls
Chief Financial Officer/Secretary
David Lowrance
Other
Badrul Chowdhury
Independent Director
Nevan Elam
Independent Director
Richard Hawkins
Independent Director
Joseph McCracken
Independent Director
David Ramsay
Independent Director
Ricky Sun
Independent Director
Annigje van Es-Johansson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SVRA
Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Savara Inc stock information, including NASDAQ:SVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SVRA stock methods without spending real money on the virtual paper trading platform.